Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tevogen Bio

Request full access

Clinical-stage specialty immunotherapy company leveraging ExacTcellTM technology platform to harness the power of CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies for…

Metuchen, United StatesFounded 2020Biotech & Life Sciences

About Tevogen Bio

Tevogen Bio is a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T-cell therapies for the treatment of infectious diseases and cancer. The firm's proprietary ExacTcell platform harnesses the power of cytotoxic T lymphocytes (CTLs) to create scalable and rapidly producible treatments.

The company's approach focuses on developing therapeutic products that are designed to be accessible and affordable, targeting a broad range of patients. Tevogen Bio is currently advancing its pipeline of product candidates for various viral infections and cancers, leveraging its expertise in cell and gene therapy. As a publicly-traded entity, its business model is centered on the research, clinical development, and eventual commercialization of its immunotherapies.

Source: Dealroom company data

At a glance

Status
Listed
Listing
Public via SPAC 2023

Tevogen Bio in the Metuchen ecosystem

Live from Dealroom

The Tevogen Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later2 investors entered at this stage

  • Semper Paratus Acquisition
  • Patel family office
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$167k

3 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Tevogen Bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.